Depending on the intrinsic cancer subtype frequency of TP53 mutations varied from 11.9% (9 out of 84) in Luminal A-like tumors, 20% (17 out of 85) in Luminal B-like (HER2-independent), 37.9% (11 out of 29) in triple-negative tumors and 55.5% (5 out of 9) in HER2-positive (non-luminal) tumors. This evidence concerns the gene ERBB2 and cancer.